What Is IGF-1 LR3?
IGF-1 LR3 is an engineered 83-amino-acid peptide based on insulin-like growth factor-1, usually shortened to IGF-1. It was designed for laboratory and biotechnology research, with changes that reduce its binding to IGF-binding proteins.
Natural IGF-1, pharmaceutical mecasermin and IGF-1 LR3 are not interchangeable. Mecasermin is recombinant human IGF-1 approved for a rare childhood growth disorder. IGF-1 LR3 is a modified analogue without an approved human use or an established programme of human treatment trials.
What does IGF-1 LR3 mean?
“IGF-1” identifies the parent growth factor. “Long” refers to the 13 extra amino acids attached to the N-terminus, the beginning of the chain. “R3” means that arginine, represented by R, replaces the amino acid normally found at position 3.
Natural mature human IGF-1 has 70 amino acids. Adding 13 gives the 83-amino-acid LR3 analogue. The position-three substitution is counted within the IGF-1 part of the molecule.
The name does not mean that the analogue is simply a longer-lasting approved IGF-1 medicine. Published experimental behaviour depends on species, route, binding proteins and assay conditions. A dependable human half-life has not been established through an approved clinical programme.
What is natural IGF-1?
IGF-1 is a growth factor made in many tissues. The liver releases circulating IGF-1 in response to growth hormone, while tissues can also make IGF-1 locally. A growth factor is a signalling protein that influences cell growth, survival, metabolism or development.
IGF-1 binds mainly to the IGF-1 receptor. This receptor is a tyrosine kinase, an enzyme-containing receptor that adds phosphate groups to proteins and starts intracellular signalling. Important pathways include PI3K-AKT and MAPK. These labels describe networks that influence metabolism, protein production, cell survival and division.
Most IGF-1 in blood is bound to IGF-binding proteins, shortened to IGFBPs. The major circulating complex also contains an acid-labile subunit. Binding proteins help carry IGF-1, prolong its circulation and regulate how much can reach receptors.
How is IGF-1 LR3 different from natural IGF-1?
The LR3 modifications greatly reduce affinity for IGF-binding proteins. Affinity describes how strongly molecules bind. LR3 can still activate the IGF-1 receptor.
In a cell culture that produces binding proteins, ordinary IGF-1 can become sequestered, meaning held away from the receptor. LR3 is less affected and may therefore appear much more potent. Potency is the amount needed to produce an experimental effect.
This design is useful in cell culture and biotechnology. It is not automatically safer or more effective in a person. Binding proteins are part of normal regulation, and bypassing them may alter tissue exposure in ways that are difficult to predict.
When was IGF-1 LR3 first documented?
Human IGF-1 was identified through work on growth-hormone-dependent “somatomedins” during the twentieth century. Somatomedin was an older term for factors that mediate some growth-hormone effects.
Recombinant DNA technology made it possible to produce and modify IGF-1. In 1992, Graham Francis and colleagues published research on recombinant fusion-protein analogues, including Long R3 IGF-I. The aim was to separate the importance of receptor binding from binding-protein interactions.
The analogue became widely used in cell culture because it could support growth and survival at low concentrations in systems where binding proteins limit ordinary IGF-1. It also entered agricultural and animal physiology research.
| Period | Development |
|---|---|
| Mid twentieth century | Growth-hormone-dependent somatomedin activity was described |
| 1970s and 1980s | IGF-1 structure, receptors and binding proteins were characterised |
| 1992 | Long R3 IGF-I was reported as a recombinant analogue with low binding-protein affinity |
| 1990s and 2000s | Cell, livestock and rodent studies used the analogue to probe IGF biology |
| 2010 | Anti-doping researchers identified a tagged LR3 product in a black-market vial |
| 2025 | A long mouse brain study changed amyloid-plaque features but did not preserve cognition |
| September 2026 | No established human treatment evidence or approval was identified |
How is IGF-1 LR3 manufactured?
At 83 amino acids, IGF-1 LR3 is usually produced through recombinant expression rather than routine stepwise chemical synthesis. Recombinant production gives a microorganism genetic instructions for making the peptide.
One approach uses the yeast Komagataella phaffii, formerly called Pichia pastoris. Researchers insert DNA encoding a fusion protein into yeast cells. A fusion partner can improve expression or handling. The cells grow in a bioreactor containing water, carbon and nitrogen sources, salts and trace nutrients.
After fermentation, the product is separated from the culture material. If a fusion partner or affinity tag is present, it must be removed to obtain the intended analogue. An affinity tag is an added sequence that helps purification. Proteases are enzymes used to cut proteins at defined sites.
Purification may use several chromatography steps. Testing must confirm the amino-acid sequence, correctly formed disulphide bonds and three-dimensional folding. A disulphide bond is a link between two cysteine amino acids. IGF-1 activity depends on the correct bond arrangement.
Raw materials include a genetically engineered production strain, growth media, nutrients, purification resins, buffers and processing enzymes. Laboratory-grade material may retain an affinity tag or have different impurity controls from a medicinal product.
A 2010 analysis found His-tagged Long R3 IGF-I in a black-market injection vial. A His-tag is a string of histidine amino acids added for purification. Its presence showed that a laboratory construct, rather than a defined medicine, had entered the illicit product supply.
Why is IGF-1 LR3 used in cell culture?
Cells grown outside the body need nutrients and growth signals. Serum, the liquid part of clotted blood, contains many undefined proteins. Biotechnology manufacturers often prefer serum-free media because it gives better control and reduces animal-derived material.
Long R3 IGF-I can support growth and survival of production cell lines in serum-free media. Its low affinity for IGF-binding proteins means lower concentrations may be effective than insulin in some systems.
This is a manufacturing use. A compound that keeps cultured cells dividing efficiently is not thereby shown to build healthy human muscle. Cell lines grow under artificial conditions and may differ greatly from adult tissues.
What have animal growth studies found?
Studies in rats, guinea pigs and livestock have examined body growth, organ size, protein metabolism and binding proteins. LR3 often produces stronger effects than native IGF-1 when binding proteins limit the ordinary molecule.
In guinea pigs, a seven-day continuous infusion study reported organ growth and reductions in circulating endogenous IGF-1, IGF-2 and IGF-binding proteins. Endogenous means made by the animal's own body. Changes in organ weight show widespread growth signalling, not selective muscle development.
Pig studies reported complex feedback, including lower endogenous growth hormone, IGF-1 and IGFBP-3. Feedback occurs when a hormone response alters the signals that produced it. These findings show that adding a growth factor can suppress parts of the natural axis.
Study design, not dosing guidance
Animal studies used continuous infusion or laboratory injections with amounts chosen for a species and research question. The figures cannot be converted into personal guidance. Scaling by body weight does not account for receptor biology, binding proteins, clearance or safety.
Cell-culture concentrations are even further removed from human exposure. They describe direct contact between a defined culture medium and cells.
Does IGF-1 LR3 build muscle?
IGF signalling can increase protein production and influence muscle-cell growth in experimental models. LR3 can stimulate protein synthesis or cell proliferation in cultured muscle cells and some animal studies.
There are no dependable controlled human trials showing that IGF-1 LR3 increases useful muscle mass, strength or physical function. Muscle size without function is not a complete clinical outcome.
Growth signalling is also not specific to skeletal muscle. The same receptor system operates in organs and abnormal cells. Claims of “local growth” after a particular injection site are not supported by reliable human evidence.
Does IGF-1 LR3 reduce body fat?
There is no established human fat-loss effect. IGF-1 and insulin pathways influence glucose and fat metabolism, but results depend on nutritional state, hormones and tissue.
Weight or body-composition observations in growing animals do not establish a treatment for adult obesity. Approved obesity medicines require dedicated human trials and safety monitoring.
What did the cancer-cachexia mouse study show?
Cachexia is severe loss of weight and muscle associated with diseases such as cancer. A mouse study examined pathway inhibitors and Long R3 IGF-I in tumour-bearing animals.
LR3 limited muscle loss in the model. It also accelerated tumour growth. The finding illustrates the central safety problem with a non-selective growth signal: supporting one tissue can also support an unwanted growing tissue.
This is an animal result and does not quantify human cancer risk. It does show why a muscle finding cannot be reported without the tumour outcome.
What did the 2025 Alzheimer-type mouse study find?
Researchers used male 5XFAD mice, a genetically engineered model that develops amyloid plaques in the brain. Amyloid plaques are deposits of a protein fragment associated with Alzheimer's disease, although a mouse plaque model does not reproduce the full human disease.
The mice received intranasal LR3 over seven months. Intranasal means delivered through the nose. Researchers reported changes in plaque structure and inflammatory-cell behaviour, but the treatment did not preserve cognitive performance.
This is an important example of a biomarker-outcome gap. Changing plaque appearance or gene pathways did not produce the hoped-for behavioural benefit in the animals.
It was not a human Alzheimer's trial and does not support intranasal use in people.
Has IGF-1 LR3 been tested in human clinical trials?
No established programme of controlled human treatment trials was identified for this review. The published literature is dominated by biochemical work, cell culture, animal physiology and analytical detection.
Without human trials, there is no validated therapeutic range, clinical pharmacokinetic profile, benefit estimate or adequate adverse-event rate. Online use and anti-doping cases are exposures, not clinical evidence.
How is IGF-1 LR3 different from mecasermin?
Mecasermin is recombinant human IGF-1 with the natural 70-amino-acid sequence. The FDA-approved product Increlex is indicated for growth failure in children with severe primary IGF-1 deficiency and selected cases involving growth-hormone gene deletion with neutralising antibodies.
IGF-1 LR3 has an extra 13-amino-acid extension and the arginine substitution. Its reduced binding-protein affinity changes its behaviour. It is not a generic version of mecasermin.
The Increlex label provides useful information about hazards that can accompany IGF-1 receptor activation, including hypoglycaemia, allergic reactions, increased pressure around the brain, enlarged tonsils and adenoids, hip growth-plate problems, scoliosis progression and concerns about abnormal growth. Hypoglycaemia means low blood glucose. Intracranial hypertension means increased pressure inside the skull.
Those labelled rates cannot be assigned directly to LR3 because the products and clinical populations differ. The label shows why an unregulated IGF analogue cannot be assumed safe.
What are the main safety concerns?
The absence of human trials leaves major uncertainties. Based on receptor biology and related medicine evidence, concerns include:
- hypoglycaemia because IGF signalling can increase glucose uptake;
- fluid retention and swelling;
- headache and possible intracranial pressure effects;
- growth of tonsil, adenoid, bone or soft tissue;
- joint and growth-plate effects in younger people;
- cardiac and organ growth;
- stimulation of existing abnormal or tumour cells;
- immune reactions to the peptide, aggregates, tags or impurities;
- interactions with insulin, growth hormone or glucose-lowering medicines.
Cancer requires careful language. There is no human evidence proving that IGF-1 LR3 causes a new cancer. IGF-1 receptor signalling can support cell survival and proliferation, and the mouse cachexia study showed accelerated tumour growth. That creates a credible unresolved risk, especially for existing or undiagnosed tumours.
Product quality is a separate concern. Recombinant material may contain host-cell proteins, residual DNA, incorrectly folded forms, endotoxin or an affinity tag. A black-market label cannot establish control of these materials.
Is IGF-1 LR3 approved?
No. IGF-1 LR3 is not an FDA-approved or UK-approved medicine. It should not be described as an approved form of IGF-1.
Mecasermin's approval cannot be transferred to LR3. Approval applies to a defined sequence, product, manufacturer, indication and clinical evidence package.
Is IGF-1 LR3 prohibited in sport?
Yes. The World Anti-Doping Agency prohibits IGF-1 and its analogues at all times under peptide hormones, growth factors, related substances and mimetics. “At all times” means both in and out of competition.
The prohibition applies regardless of whether a product is labelled for research or supplied by a clinic. Tested athletes remain responsible for substances found in their samples.
What benefits are claimed, and what does the evidence support?
| Claim | What the evidence supports |
|---|---|
| Builds muscle | Cell and animal anabolic effects; no established human benefit |
| Reduces body fat | No dependable human evidence |
| Repairs injury | No controlled human evidence |
| Acts only where injected | No reliable evidence; growth-factor signalling is not shown to remain local |
| Improves cognition | A 2025 mouse study changed plaque features but did not preserve cognition |
| Has mecasermin's approval | False; LR3 is a different unapproved analogue |
| Is safe because IGF-1 is natural | Not supported; the analogue is modified to evade normal binding-protein regulation |
What research would be needed next?
Any human programme would first need a well-characterised pharmaceutical product, repeated-exposure toxicology and assessment of glucose, organ growth and tumour-related risks. Pharmacokinetic studies would need methods able to distinguish LR3 from natural IGF-1.
Clinical trials would require a specific medical condition and outcomes that measure function, not only cell growth or biomarkers. Long-term surveillance would be particularly important because growth-related harm might not appear immediately.
How does IGF-1 signalling overlap with insulin?
The IGF-1 receptor and insulin receptor are related tyrosine-kinase receptors. Cells can also form hybrid receptors containing part of each. IGF-1 LR3 is designed mainly around IGF-1 receptor activity, but the connected pathways help explain metabolic effects.
Activating these systems can move glucose into tissues and reduce blood glucose. The response depends on food intake, insulin sensitivity, other hormones and concurrent medicines. This is why hypoglycaemia is a recognised risk with mecasermin and a credible concern for an untested analogue.
Symptoms of low blood glucose can include sweating, shaking, hunger, confusion, weakness, seizure and loss of consciousness. A mechanism-based risk is not a measured incidence for LR3, because adequate human exposure data are absent.
Why do IGF-binding proteins exist?
Six high-affinity IGF-binding proteins help control transport, stability and access to receptors. IGFBP-3 carries most circulating IGF-1 in a larger complex with the acid-labile subunit.
Binding can limit immediate receptor activity while prolonging the time IGF-1 remains in circulation. Some binding proteins also act within tissues or independently of IGF-1.
LR3 was engineered to bind these proteins weakly. That makes it a useful experimental tool because researchers can observe receptor effects with less buffering. It also means that natural binding-protein control cannot be assumed to protect against excessive or misplaced signalling.
What is known about the human pharmacokinetics of LR3?
There is no established regulator-reviewed human pharmacokinetic profile. Frequently repeated online half-life figures are not supported by a defined human clinical programme.
Weak binding to IGFBPs does not automatically mean a longer circulation time. Binding proteins can protect natural IGF-1 from rapid removal. Some animal work found that LR3 was cleared more quickly from blood while producing strong tissue effects because more remained available to receptors.
Distribution can also differ by organ and species. A blood concentration does not reveal receptor exposure in muscle, heart, kidney or a tumour.
Why is organ growth not the same as healthy muscle gain?
An anabolic signal increases the building of tissue. Clinical value depends on which tissue grows, whether function improves and what happens elsewhere.
Animal LR3 studies have reported changes in visceral-organ weights as well as body growth. Visceral organs include the liver, kidneys, intestines and heart. Enlargement may represent adaptation, fluid, cell enlargement or increased cell number and is not automatically beneficial.
Strength depends on nerves, tendons, muscle architecture and training as well as muscle protein. A change in cell protein synthesis cannot predict injury risk or physical performance in people.
How should tumour-related evidence be interpreted?
The IGF-1 receptor helps some cells survive and divide. Many cancers alter this pathway, but tumour biology differs by type and individual tumour.
The mouse cachexia experiment is directly relevant because it measured both muscle and tumour outcomes under LR3 exposure. Preserving muscle while accelerating tumour growth was a harmful trade-off in that model.
It does not calculate the human risk of developing cancer and does not prove that a brief exposure initiates a tumour. It shows why people with existing cancer, prior cancer or an undiagnosed growth cannot be assumed safe.
Long-term human research would need to track new diagnoses and growth of existing lesions. Short physique studies would be inadequate for this question.
What does the black-market vial study tell us?
Anti-doping scientists analysed a product labelled as Long R3 IGF-I and found the analogue with a six-histidine purification tag and linker still attached. The product therefore did not match an untagged 83-amino-acid description.
The tag may change molecular mass, immune recognition or behaviour. More broadly, the finding shows that a material intended as a laboratory construct can reach consumers without pharmaceutical redesign.
One vial cannot describe every product. It demonstrates why a label and a basic purity certificate cannot substitute for identity testing and regulated manufacture.
How do anti-doping laboratories detect IGF analogues?
Natural IGF-1 is present in the body, so detection is more complex than finding a completely foreign small molecule. Laboratories use immunopurification to isolate growth factors and mass spectrometry to identify sequence-specific fragments.
Immunopurification uses antibodies to capture a target from blood or urine. Mass spectrometry then measures molecular fragments. Modified analogues can provide signatures that differ from endogenous IGF-1.
Detection research shows analytical exposure. It does not provide evidence that the substance improves performance or is safe. Anti-doping rules prohibit the class because of growth-related effects and health and fairness concerns.
How should the evidence be ranked?
| Evidence type | What LR3 research shows | What remains unknown |
|---|---|---|
| Receptor and binding assays | Low IGFBP affinity and retained IGF-1 receptor activity | Whole-person balance of effects |
| Cell culture | Strong growth and survival signals in selected cells | Human muscle, organ and tumour response |
| Animal studies | Growth, feedback, organ and disease-model effects | Safe human exposure and clinical benefit |
| Black-market analysis | At least one product contained tagged laboratory material | Contents and risks of other products |
| Human clinical trials | No established controlled programme | Efficacy, pharmacokinetics and adverse-event rates |
What would an ethical human programme need to address?
A trial would need a serious medical rationale strong enough to justify the growth and glucose risks. Existing approved treatments would form the comparison, not an inactive placebo where withholding care would be unethical.
Researchers would monitor glucose, heart structure, organ size, eye findings, joint symptoms and abnormal tissue growth. Cancer screening and long-term follow-up would be necessary.
The modified molecule would need assays that separate it from natural IGF-1 and detect neutralising antibodies. Without those foundations, a trial could not explain either benefit or harm reliably.
Frequently asked questions
Is IGF-1 LR3 a peptide?
Yes. It is an engineered 83-amino-acid peptide growth-factor analogue.
Is IGF-1 LR3 the same as IGF-1?
No. It contains a 13-amino-acid extension and an arginine substitution that reduce binding to IGF-binding proteins.
Is IGF-1 LR3 the same as mecasermin?
No. Mecasermin is recombinant human IGF-1 with the natural sequence and a defined approved use. LR3 is a modified, unapproved analogue.
Does IGF-1 LR3 build muscle in people?
There is no dependable controlled human evidence establishing that benefit.
Can IGF-1 LR3 cause low blood sugar?
Direct human rates are unknown, but hypoglycaemia is a biologically credible concern because IGF signalling affects glucose and the approved IGF-1 medicine carries a strong warning.
Does IGF-1 LR3 increase cancer risk?
Human risk is unknown. Growth signalling can support tumour cells, and LR3 accelerated tumour growth in one mouse cachexia model.
Is IGF-1 LR3 FDA approved?
No.
Is IGF-1 LR3 banned in sport?
Yes. IGF-1 and its analogues are prohibited at all times under World Anti-Doping Agency rules.
Sources
Research reviewed through September 2026.